# Mirum Pharmaceuticals, Inc.: overview

MIRM · Nasdaq · CIK 1759425 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mirm.md) · [Financials](/companies/mirm/financials.md) · [Filings](/companies/mirm/filings.md) · [Insiders](/companies/mirm/insiders.md)

Latest reported revenue: [$176.2m](/filings/0001759425-26-000045.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001759425-26-000045).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [90.4](/filings/0001759425-25-000054.md) | [99.4 d](/filings/0001759425-26-000013.md) | [112](/filings/0001759425-26-000037.md) | [128](/filings/0001759425-26-000045.md) | [133](/filings/0001759425-25-000054.md) | [149 d](/filings/0001759425-26-000013.md) | [160](/filings/0001759425-26-000037.md) | [176](/filings/0001759425-26-000045.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(14.0%)](/filings/0001759425-25-000054.md) | [(24.4%) d](/filings/0001759425-26-000013.md) | [(13.6%)](/filings/0001759425-26-000037.md) | [(3.9%)](/filings/0001759425-26-000045.md) | [2.0%](/filings/0001759425-25-000054.md) | [(3.1%) d](/filings/0001759425-26-000013.md) | [(493.8%)](/filings/0001759425-26-000037.md) | [(24.1%)](/filings/0001759425-26-000045.md) |
| Net margin | % | [(15.8%)](/filings/0001759425-25-000054.md) | [(23.9%) d](/filings/0001759425-26-000013.md) | [(13.2%)](/filings/0001759425-26-000045.md) | [(4.6%)](/filings/0001759425-26-000045.md) | [2.2%](/filings/0001759425-25-000054.md) | [(3.8%) d](/filings/0001759425-26-000013.md) | [(494.2%)](/filings/0001759425-26-000045.md) | [(38.1%)](/filings/0001759425-26-000045.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0001759425-25-000054.md) | not reported | [(0.30)](/filings/0001759425-26-000037.md) | [(0.12)](/filings/0001759425-26-000045.md) | [0.05](/filings/0001759425-25-000054.md) | not reported | [(13.43)](/filings/0001759425-26-000037.md) | [(1.06)](/filings/0001759425-26-000045.md) |
| Free cash flow | $m | [3.8 d](/filings/0001759425-25-000054.md) | [(5.1) d](/filings/0001759425-26-000013.md) | [(2.0)](/filings/0001759425-26-000037.md) | [11.9 d](/filings/0001759425-26-000045.md) | [39.5 d](/filings/0001759425-25-000054.md) | [5.5 d](/filings/0001759425-26-000013.md) | [(229)](/filings/0001759425-26-000037.md) | [(44.3) d](/filings/0001759425-26-000045.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [19.1](/filings/0000950170-24-032289.md) | [77.1](/filings/0001759425-25-000014.md) | [186](/filings/0001759425-26-000013.md) | [337](/filings/0001759425-26-000013.md) | [521](/filings/0001759425-26-000013.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(906.1%)](/filings/0000950170-24-032289.md) | [(170.3%)](/filings/0001759425-25-000014.md) | [(58.6%)](/filings/0001759425-26-000013.md) | [(26.0%)](/filings/0001759425-26-000013.md) | [(4.2%)](/filings/0001759425-26-000013.md) |
| Net margin | % | [(438.9%)](/filings/0000950170-24-032289.md) | [(176.0%)](/filings/0001759425-25-000014.md) | [(87.7%)](/filings/0001759425-26-000013.md) | [(26.1%)](/filings/0001759425-26-000013.md) | [(4.5%)](/filings/0001759425-26-000013.md) |
| Diluted EPS | $ per share | [(2.77)](/filings/0000950170-24-032289.md) | [(4.02)](/filings/0001759425-25-000014.md) | [(4.00)](/filings/0001759425-26-000013.md) | [(1.85)](/filings/0001759425-26-000013.md) | [(0.47)](/filings/0001759425-26-000013.md) |
| Free cash flow | $m | [(133)](/filings/0000950170-24-032289.md) | [(120)](/filings/0001759425-25-000014.md) | [(71.1)](/filings/0001759425-26-000013.md) | [9.3](/filings/0001759425-26-000013.md) | [54.9](/filings/0001759425-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mirm/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $899.1m | 7,679,684 |  | Unchanged |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $691.7m | 5,909,184 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $641.8m | 6,945,813 |  | Not compared |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $513.9m | 4,390,063 |  | Added +543,533 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $429.7m | 3,670,314 |  | Added +1,704,939 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $278.3m | 2,377,019 |  | Added +944,936 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $263.9m | 2,254,109 |  | Reduced −160,667 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $254.1m | 2,170,689 |  | Added +226,408 |
| [WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC](/funds/1644956.md) | 2026-06-30 | $164.5m | 1,404,741 |  | Added +1,069,072 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $163.2m | 1,393,908 |  | Added +133,905 |

## Recent filings

[All 666 filings](/companies/mirm/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-26 | 16:47 ET | [8-K](/filings/0001759425-26-000054.md) | 8.01 Other events | 0001759425-26-000054 |
| 2026-10-13 | 08:09 ET | [8-K](/filings/0001759425-26-000051.md) | 8.01 Other events | 0001759425-26-000051 |
| 2026-09-28 | 08:02 ET | [8-K](/filings/0001759425-26-000049.md) | 8.01 Other events | 0001759425-26-000049 |
| 2026-09-08 | 08:34 ET | [8-K](/filings/0001759425-26-000047.md) | 5.02 Departure or appointment of officers or directors | 0001759425-26-000047 |
| 2026-08-05 | 16:06 ET | [10-Q](/filings/0001759425-26-000045.md) | Quarterly report, period 2026-06-30 | 0001759425-26-000045 |
| 2026-08-05 | 16:02 ET | [8-K](/filings/0001759425-26-000044.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-26-000044 |
| 2026-06-18 | 16:05 ET | [8-K](/filings/0001193125-26-275811.md) | 5.07 Shareholder vote results | 0001193125-26-275811 |
| 2026-05-18 | 16:06 ET | [8-K](/filings/0001193125-26-228902.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-228902 |
| 2026-05-06 | 16:07 ET | [10-Q](/filings/0001759425-26-000037.md) | Quarterly report, period 2026-03-31 | 0001759425-26-000037 |
| 2026-05-06 | 16:04 ET | [8-K](/filings/0001759425-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-26-000036 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001759425-26-000013.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/df9a5696-ee6a-41d0-b635-1d124bb29c7a)

## About the filer

- CIK: 1759425
- Tickers: MIRM
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:48 ET. No prices; not investment advice.